News

Molecular Insight has presented clinical data on prostate cancer diagnostic at the 2009 annual meeting of the Society of Nuclear Medicine (SNM) in Toronto. The clinical data was

Nuvo has entered into a license and development agreement with Covidien, to market and sell Pennsaid, and its follow-on product, Pennsaid Plus, in the US. Under the agreement,

Qiagen has entered into an agreement to transfer distribution rights for the Olerup sequence specific primer (SSP) product line and the related assets to Olerup International, a subsidiary

Clarient has announced the launch of a new gene mutation test, that can help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC). The

Peregrine has presented the data for ongoing trail for brain cancer at Society of Nuclear Medicine 2009 Annual Meeting. The study supports the potential for Cotara to treat

AlphaRx and Gaia have provided latest updates on GAI-122, an investigational injectable nano-emulsion formulated with AlphaRx’s proprietary drug delivery technology. Gaia plans to initiate a clinical development program

HEALTHPOINT has enrolled the first of a planned 235 subjects into a Phase-II dose response study, investigating an experimental, cell-based wound therapy, HP802-247. It is intended for the

Alexza Pharmaceuticals has announced that it has exercised its option to purchase all of the equity of Symphony Allegro. The purchase of Symphony Allegro, which is subject to

Headquartered in Massechuset, Palomar Medical has declared that the US Patent and Trademark Office has confirmed the validity of 56 claims in the re-examination of US Patent No.